OctoPlus N.V.
Hieronder vindt u informatie uit het register openbaarmaking voorwetenschap. Deze informatie is door de organisatie verstrekt.
Publicatie datum
23 apr 2009 - 15:54
Statutaire naam
OctoPlus N.V.
Titel
Shareholders OctoPlus appoint James Gale to Supervisory Board
Bericht
OctoPlus N.V. (“OctoPlus” or “the Company”) (Euronext: OCTO) announces today that the Annual General Meeting of Shareholders (the “Meeting”) has appointed Mr. James Gale to the Board of Supervisory Directors. The Meeting also reappointed Mr. Philip Smith and among others approved changes to the Company’s Articles of Association according to a proposal by the Company, to reflect changes in the Company’s share capital and corporate governance as a result of the February 2009 private placement.
Mr. Gale has been appointed for a period of four years. Mr. Gale is Managing Partner at Signet Healthcare, one of the major investors in OctoPlus’ February 2009 private placement. He is a supervisory director at AlpexPharma S.A., Cedarburg Pharmaceuticals Inc., Cydex Pharmaceuticals Inc., SpePharm B.V. and Paladin Laboratories Inc. Signet currently holds 16.6% of OctoPlus’ outstanding shares. Mr. Gale holds no shares and no rights to acquire shares in the capital of OctoPlus. Due to his position within Signet, Mr. Gale is not independent within the meaning of the Dutch Corporate Governance Code.
Mr. Smith was appointed as member of the Board of Supervisory Directors in 2005, for a period of four years and has now been reappointed for a period of four years. Mr. Smith holds no shares and no rights to acquire shares in the capital of OctoPlus. Mr. Smith is independent within the meaning of the Dutch Corporate Governance Code.
Datum laatste update: 25 maart 2025